Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Echinocandins inhibit the synthesis of β-1,3- d -glucan in Candida and are the first-line therapy in numerous clinical settings. Their use is limited by poor oral bioavailability, and they are available only as intravenous therapies. Derivatives of enfumafungin are novel orally bioavailable glucan synthase inhibitors. We performed an in vivo pharmacodynamic (PD) evaluation with a novel enfumafungin derivative, SCY-078 (formerly MK-3118), in a well-established neutropenic murine model of invasive candidiasis against C. albicans , C. glabrata , and C. parapsilosis . The SCY-078 MICs varied 8-fold. Oral doses of 3.125 to 200 mg/kg SCY-078 salt in sterile water produced peak levels of 0.04 to 2.66 μg/ml, elimination half-lives of 5.8 to 8.5 h, areas under the concentration-time curve from 0 to 24 h (AUC 0–24 h ) of 0.61 to 41.10 μg · h/ml, and AUC from 0 to infinity (AUC 0—∞ ) values of 0.68 to 40.31 μg · h/ml. The pharmacokinetics (PK) were approximately linear over the dose range studied. Maximum response ( E max ) and PK/PD target identification studies were performed with 4 C. albicans , 4 C. glabrata , and 3 C. parapsilosis isolates. The PD index AUC/MIC was explored by using total ( t AUC) and free ( f AUC) drug concentrations. The maximum responses were 4.0, 4.0, and 4.3 log 10 CFU/kidney reductions for C. albicans , C. glabrata , and C. parapsilosis , respectively. The AUC/MIC was a robust predictor of efficacy ( R 2 , 0.53 to 0.91). The 24-h PD targets were a static dose of 63.5 mg/kg, a t AUC/MIC of 500, and an f AUC/MIC of 1.0 for C. albicans ; a static dose of 58.4 mg/kg, a t AUC/MIC of 315, and an f AUC/MIC of 0.63 for C. glabrata ; and a static dose of 84.4 mg/kg, a t AUC/MIC of 198, and an f AUC/MIC of 0.40 for C. parapsilosis . The mean f AUC/MIC values associated with a 1-log kill endpoint against these species were 1.42, 1.26, and 0.91 for C. albicans , C. glabrata , and C. parapsilosis , respectively. The static and 1-log kill endpoints were measured relative to the burden at the start of therapy. The static and 1-log kill doses, as well as the total and free drug AUC/MIC PD targets, were not statistically different between species but were numerically lower than those observed for echinocandins. SCY-078 is a promising novel oral glucan synthase inhibitor against Candida species, and further investigation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“50 INTRODUCTION 51 Candida species are the most commonly encountered fungal pathogens in the hospital 52 setting, the 4 most common cause of nosocomial bloodstream infection, and 53 associated with the highest mortality among infections caused by bloodstream isolates 54 (25, 26, 30).”
BackgroundPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 2×
“Clinically, outcomes in patients treated with echinocandins against various forms of candidiasis, including IC, have demonstrated the equivalence or superiority of these compounds versus triazoles or amphotericin B (1, 11).”
BackgroundSelf-citationDenning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“structural component in Candida species (12, 14, 15, 34).”
BackgroundHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Self-citationPharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180 · cited 1×
“A neutropenic, murine, disseminated candidiasis model was used for 109 treatment studies (7-9).”
MethodSelf-citationIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
Self-citationIn vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1187-1192.2003 · Cited by 100
Self-citationDiscovery of a Novel Class of Orally Active Antifungal β-1,3- d -Glucan Synthase Inhibitors
Walker, S. S., Xu, Y., Triantafyllou, I., Waldman, M. F., Mendrick, C., Brown, N., Mann, P., Chau, A., Patel, R., Bauman, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00432-11 · Cited by 75
Cited by
Antifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Fungal Cell Wall: Emerging Antifungals and Drug Resistance.
Lima, S. L., Colombo, A. L., & de Almeida Junior, J. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02573 · Cited by 223
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
Metadata
- Authors
- Lepak, A. J., Marchillo, K., & Andes, D. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-02
- Volume
- 59
- Issue
- 2
- Pages
- 1265-1272
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2143849345
- Cited by
- 95
- References
- 14
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.